Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial

Ultragenyx Pharmaceutical shares fell more than 40% in premarket after its late-stage trial for a neurodevelopmental disorder treatment failed, undermining a key growth bet. The setback is a major negative catalyst for the company’s clinical pipeline and near-term outlook. The magnitude of the drop suggests investors repriced the probability of success for future revenue streams.